详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Phosphorylation of LIFR promotes prostate cancer progression by activating the AKT pathway.

文献详情

资源类型：

Pubmed体系：

作者：

机构： [a]Precise Genome Engineering Center, School of Life Sciences, Guangzhou University, Guangzhou, 510006, China [b]Department of Urology, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, 200080, China [c]Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, 320 Yue Yang Road, Shanghai, 200031, China [d]Department of Urology and Andrology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200001, China [e]Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China [f]Department of Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China [g]National Engineering Research Center for Biomaterials, Sichuan University, Chengdu, 610065, China [h]Department of Radiology, West China Hospital, Sichuan University, Chengdu, 610065, China

出处：

DOI：

ISSN：

关键词： LIFR Phosphorylation Prostate cancer AKT

摘要：

Prostate cancer (PCa) is the most common solid organ malignancy among men, outnumbering both lung and colorectal cancer, and it is the second leading cause of male tumor-related death in the United States due to high metastasis. Recently, leukemia inhibitory factor receptor (LIFR) has been found to play roles in multiple types of cancer. However, the roles of LIFR in the progression of PCa remain to be revealed. In this study, we found that LIFR plays an oncogenic role in PCa. The phosphorylation of LIFR at S1044 contributes to subsequent activation of the AKT pathway, inducing the expression of a series of proliferation and metastatic genes. Additionally, LIFR-S1044 is phosphorylated by ERK2 but not ERK1. The signal intensity of pLIFR-S1044 and pAKT S473 in PCa tissue displays a tight positive correlation. The ERK2/LIFR/AKT axis modulates PCa progression and offers a promising therapeutic and diagnostic target for PCa. Copyright © 2019 Elsevier B.V. All rights reserved.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2019]版：

大类 | 2 区

医学

小类 | 2 区肿瘤学

最新[2023]版：

大类 | 1 区

医学

小类 | 2 区肿瘤学

第一作者：

第一作者机构： [a]Precise Genome Engineering Center, School of Life Sciences, Guangzhou University, Guangzhou, 510006, China [b]Department of Urology, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, 200080, China

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Mitochondrial p53 phosphorylation induces Bak-mediated and caspase-independent cell death [2]AP4 modulated by the PI3K/AKT pathway promotes prostate cancer proliferation and metastasis of prostate cancer via upregulating L-plastin [3]SAE1 promotes human glioma progression through activating AKT SUMOylation-mediated signaling pathways [4]Breviscapine suppresses the growth and metastasis of prostate cancer through regulating PAQR4-mediated PI3K/Akt pathway [5]The P2 purinoceptors in prostate cancer [6]Phosphorylation and changes in the distribution of nucleolin promote tumor metastasis via the PI3K/Akt pathway in colorectal carcinoma [7]Sin1 promotes proliferation and invasion of prostate cancer cells by modulating mTORC2-AKT and AR signaling cascades [8]前列腺癌筛查专家共识 [9]CARK1 mediates ABA signaling by phosphorylation of ABA receptors. [10]rAAV-delivered PTEN therapeutics for prostate cancer.